Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
PURPOSE: Lower serum testosterone levels correlate with improved cause specific survival and longer time to progression in year 1 of continuous androgen deprivation in men with prostate cancer. ICELAND was a large European study demonstrating the efficacy of leuprorelin (Eligard®) during continuous...
Published in: | Journal of Urology |
---|---|
Main Authors: | , , , , , |
Other Authors: | , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Wolters Kluwer
2017
|
Subjects: | |
Online Access: | http://hdl.handle.net/2078.1/188680 https://doi.org/10.1016/j.juro.2017.05.072 |
id |
ftunistlouisbrus:oai:dial.uclouvain.be:boreal:188680 |
---|---|
record_format |
openpolar |
spelling |
ftunistlouisbrus:oai:dial.uclouvain.be:boreal:188680 2024-05-12T08:05:45+00:00 Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study. Tombal, Bertrand Cornel, Erik B Persad, Raj Stari, Anny Gómez Veiga, Francisco Schulman, Claude UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation UCL - (SLuc) Service d'urologie 2017 http://hdl.handle.net/2078.1/188680 https://doi.org/10.1016/j.juro.2017.05.072 eng eng Wolters Kluwer boreal:188680 http://hdl.handle.net/2078.1/188680 doi:10.1016/j.juro.2017.05.072 info:pmid/28552710 urn:ISSN:0022-5347 urn:EISSN:1527-3792 info:eu-repo/semantics/restrictedAccess The Journal of Urology, Vol. 198, no. 5, p. 1054-1060 (2017) leuprolide mortality prostate-specific antigen prostatic neoplasms testosterone info:eu-repo/semantics/article 2017 ftunistlouisbrus https://doi.org/10.1016/j.juro.2017.05.072 2024-04-18T17:34:46Z PURPOSE: Lower serum testosterone levels correlate with improved cause specific survival and longer time to progression in year 1 of continuous androgen deprivation in men with prostate cancer. ICELAND was a large European study demonstrating the efficacy of leuprorelin (Eligard®) during continuous androgen deprivation. In this post hoc analysis we investigated serum testosterone levels within year 1 of continuous androgen deprivation to determine survival and time to progression. MATERIALS AND METHODS: In ICELAND (ClinicalTrials.gov NCT00378690) patients with locally advanced or relapsing nonmetastatic prostate cancer and with prostate specific antigen 1 ng/ml or less following 6-month induction with leuprorelin 3-month depot 22.5 mg (plus bicalutamide 50 mg per day for 1 month) were randomized 1:1 to continuous androgen deprivation (361) or intermittent androgen deprivation (340) with leuprorelin for 36 months. Patients receiving continuous androgen deprivation were stratified by minimum, median and maximum testosterone levels during year 1 of therapy into 20 or less, greater than 20 to 50 and greater than 50 ng/dl subgroups. Cause specific survival and time to prostate specific antigen (castrate resistant prostate cancer) progression were analyzed. RESULTS: A total of 90.1%, 83.5% and 74.5% of patients receiving continuous androgen deprivation achieved minimum, median and maximum serum testosterone levels of 20 ng/dl or less, respectively. Cause specific survival rates and time to prostate specific antigen progression did not differ among the testosterone subgroups. CONCLUSIONS: In patients receiving continuous androgen deprivation cause specific survival and time to prostate specific antigen progression did not differ according to testosterone levels in year 1 of therapy. This finding may in part be due to the induction period and the effectiveness of leuprorelin in lowering testosterone. Article in Journal/Newspaper Iceland DIAL@USL-B (Université Saint-Louis, Bruxelles) Journal of Urology 198 5 1054 1060 |
institution |
Open Polar |
collection |
DIAL@USL-B (Université Saint-Louis, Bruxelles) |
op_collection_id |
ftunistlouisbrus |
language |
English |
topic |
leuprolide mortality prostate-specific antigen prostatic neoplasms testosterone |
spellingShingle |
leuprolide mortality prostate-specific antigen prostatic neoplasms testosterone Tombal, Bertrand Cornel, Erik B Persad, Raj Stari, Anny Gómez Veiga, Francisco Schulman, Claude Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study. |
topic_facet |
leuprolide mortality prostate-specific antigen prostatic neoplasms testosterone |
description |
PURPOSE: Lower serum testosterone levels correlate with improved cause specific survival and longer time to progression in year 1 of continuous androgen deprivation in men with prostate cancer. ICELAND was a large European study demonstrating the efficacy of leuprorelin (Eligard®) during continuous androgen deprivation. In this post hoc analysis we investigated serum testosterone levels within year 1 of continuous androgen deprivation to determine survival and time to progression. MATERIALS AND METHODS: In ICELAND (ClinicalTrials.gov NCT00378690) patients with locally advanced or relapsing nonmetastatic prostate cancer and with prostate specific antigen 1 ng/ml or less following 6-month induction with leuprorelin 3-month depot 22.5 mg (plus bicalutamide 50 mg per day for 1 month) were randomized 1:1 to continuous androgen deprivation (361) or intermittent androgen deprivation (340) with leuprorelin for 36 months. Patients receiving continuous androgen deprivation were stratified by minimum, median and maximum testosterone levels during year 1 of therapy into 20 or less, greater than 20 to 50 and greater than 50 ng/dl subgroups. Cause specific survival and time to prostate specific antigen (castrate resistant prostate cancer) progression were analyzed. RESULTS: A total of 90.1%, 83.5% and 74.5% of patients receiving continuous androgen deprivation achieved minimum, median and maximum serum testosterone levels of 20 ng/dl or less, respectively. Cause specific survival rates and time to prostate specific antigen progression did not differ among the testosterone subgroups. CONCLUSIONS: In patients receiving continuous androgen deprivation cause specific survival and time to prostate specific antigen progression did not differ according to testosterone levels in year 1 of therapy. This finding may in part be due to the induction period and the effectiveness of leuprorelin in lowering testosterone. |
author2 |
UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation UCL - (SLuc) Service d'urologie |
format |
Article in Journal/Newspaper |
author |
Tombal, Bertrand Cornel, Erik B Persad, Raj Stari, Anny Gómez Veiga, Francisco Schulman, Claude |
author_facet |
Tombal, Bertrand Cornel, Erik B Persad, Raj Stari, Anny Gómez Veiga, Francisco Schulman, Claude |
author_sort |
Tombal, Bertrand |
title |
Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study. |
title_short |
Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study. |
title_full |
Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study. |
title_fullStr |
Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study. |
title_full_unstemmed |
Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study. |
title_sort |
clinical outcomes and testosterone levels following continuous androgen deprivation in patients with relapsing or locally advanced prostate cancer: a post hoc analysis of the iceland study. |
publisher |
Wolters Kluwer |
publishDate |
2017 |
url |
http://hdl.handle.net/2078.1/188680 https://doi.org/10.1016/j.juro.2017.05.072 |
genre |
Iceland |
genre_facet |
Iceland |
op_source |
The Journal of Urology, Vol. 198, no. 5, p. 1054-1060 (2017) |
op_relation |
boreal:188680 http://hdl.handle.net/2078.1/188680 doi:10.1016/j.juro.2017.05.072 info:pmid/28552710 urn:ISSN:0022-5347 urn:EISSN:1527-3792 |
op_rights |
info:eu-repo/semantics/restrictedAccess |
op_doi |
https://doi.org/10.1016/j.juro.2017.05.072 |
container_title |
Journal of Urology |
container_volume |
198 |
container_issue |
5 |
container_start_page |
1054 |
op_container_end_page |
1060 |
_version_ |
1798848110595670016 |